Log in to save to my catalogue

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal...

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_926891461

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

About this item

Full title

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2008, Vol.9 (1), p.23-28

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

Summary Background The Breast International Group (BIG) 1-98 trial (a randomised double-blind phase III trial) has shown that letrozole significantly improves disease-free survival (DFS) compared with tamoxifen in postmenopausal women with endocrine-responsive early breast cancer. Our aim was to establish whether the benefit of letrozole versus tam...

Alternative Titles

Full title

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_926891461

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_926891461

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(07)70386-8

How to access this item